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Context: With the growing public health concern over rising rates of opioid abuse, physicians 
have a responsibility to incorporate safeguards into their practice to minimize the potential for 
opioid misuse, abuse, and diversion. Patient-specific treatment regimens should include steps 
to monitor treatment success with regard to optimal pain management as well as inappropri-
ate use of opioids and other substances. Opioid formulations designed to be less attractive for 
abuse are also being developed. While future studies are needed to determine the impact of 
such formulations in addressing the issue of opioid misuse in the community as a whole, the 
experience of practitioners who have utilized these formulations can highlight the practical steps 
to incorporate such formulations into the everyday patient-care setting.
Purpose: The purpose of this report is to describe experience in managing patients with chronic, 
moderate-to-severe pain using morphine sulfate and naltrexone hydrochloride extended release 
capsules (MS-sNT) (EMBEDA®, King Pharmaceuticals® Inc, Bristol, TN, which was acquired 
by Pfizer Inc, New York, NY, in March 2011), a formulation designed with features to deter 
abuse/misuse, in a community-based pain management clinic.
Case presentations: Case reports demonstrating a clinical management plan for assessment, 
initial interview procedures, explanation/discussion of proposed therapies, patients’ treatment 
goals, conversion to MS-sNT, and titration and treatment outcomes are provided.
Results: The management approach yielded successful outcomes including pain relief, improved 
quality of life, treatment satisfaction, and patient acceptance of a formulation designed to deter 
abuse/misuse.
Discussion: The cases presented demonstrate that the communication accompanying complete 
pretreatment assessment, goal-setting and expectations, and attention to individual patient 
needs can enable optimization of pain-related outcomes, resulting in improved quality of life 
for patients and fostering patient acceptance of formulations designed to help address opioid 
abuse/misuse issues in the community at large.
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Introduction
Opioids play an important role in the management of chronic, moderate-to-severe pain 
in carefully selected and monitored patients.1,2 Opioid therapy may be considered for 
some patients who cannot achieve pain relief or obtain as favorable a benefit-to-harm 
evaluation with alternative therapies, and may be part of a multimodal treatment 
plan.1 As chronic pain negatively affects physical functioning, sleep pattern, social 
activity, and occupational productivity, contemporary pain management focuses on 
reducing pain while improving functional ability and psychological wellbeing.1–3 
Knowledge of how pain is affecting the patient can help physicians develop and/or 
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refine a   patient-specific treatment strategy, determine whether 
referral to a pain specialist or other specialist is necessary, 
and set realistic treatment goals.3
In addition to the challenges of developing a patient-
specific opioid treatment regimen, clinicians must respon-
sibly prescribe in the context of the current growing public 
health concern over soaring rates of opioid abuse.4 In the 
United States during 2009, among those aged 12 years or 
older, 2.2 million persons initiated illicit drug use with pain 
relievers, a rate surpassed only by those initiating with mari-
juana (2.4 million).5 Studies performed among patients being 
treated for chronic pain reveal rates of opioid and illicit drug 
abuse that vary widely (∼3%–32%).6–9 While the Federation 
of State Medical Boards of the United States encourages 
the use of opioids when appropriate for patients with pain, 
it also notes the responsibility of physicians to incorporate 
safeguards into their practices to minimize the potential for 
their abuse and diversion.10
Therefore, a major challenge for the practitioner is to 
optimize pain management, using opioids when appropriate, 
by taking steps to both monitor treatment success and assess 
for inappropriate use of opioids or other substances.
Current guidelines for pain management include several 
recommendations for clinicians based on the universal pre-
cautions approach, which recognizes that it is not always 
possible to determine which patients misuse, abuse, and 
divert prescription opioids or those who are likely to do 
so.11,12 Such an approach universally used with all patients 
may decrease the number of opioid abuse problems that go 
unrecognized and can reduce the stigma that patients may 
feel about the types of questions asked at an initial physician–
patient interview11 or a request, for example, to undergo a 
urine drug screen (UDS). An important component of a pain 
management plan, both to optimize pain management and 
minimize risks for misuse, abuse, and diversion of opioid 
analgesics, is patient education and communication.1
Formulations that are less attractive for misuse, abuse, and 
diversion are also being developed by several pharmaceuti-
cal companies and may be used as part of a comprehensive 
risk management plan by providing one step in discouraging 
prescription opioid misuse, abuse, and diversion.13,14 The mor-
phine sulfate and naltrexone hydrochloride extended release 
capsule (MS-sNT) (EMBEDA®, King Pharmaceuticals® Inc, 
Bristol, TN, which was acquired by Pfizer Inc, New York, NY, 
in March 2011) is indicated for the management of moderate-
to-severe pain when a continuous, around-the-clock opioid 
analgesic is needed for an extended period of time.15 MS-sNT 
consists of pellets of extended-release morphine sulfate, 
each containing a core of sequestered naltrexone, an opioid 
antagonist.15,16 Taken as directed, the morphine provides 
analgesic relief, while the naltrexone remains sequestered;17 
but, if tampered with by crushing, the naltrexone is released 
and available to mitigate the morphine-induced subjective 
effects.16,18 Studies performed in nondependent recreational 
opioid users have indicated that the quantity of naltrexone 
released upon tampering is sufficient to mitigate the desired 
subjective effects of the morphine when administered orally 
or intravenously.16,19 While similar studies have not been 
completed in opioid-dependent recreational users, product 
labeling and case reports published on two opioid-dependent 
patients indicate that consumption of MS-sNT that has 
been tampered with by crushing or chewing may result in 
opioid withdrawal. This is an important caution for patients 
prescribed MS-sNT. It is not known whether knowledge of 
the potential for withdrawal symptoms might further deter 
individuals who might misuse or abuse MS-sNT.20,21
The objective of this report is to describe a successful 
approach to managing referred patients with chronic, mod-
erate-to-severe pain with inadequate response to previous 
opioid therapy, focusing on education and communication 
while using MS-sNT.
Case reports
Case 1
A 44-year-old woman with active breast cancer undergoing 
radiation and chemotherapy had uncontrolled generalized 
bone pain, particularly sternum. The patient had been on esca-
lating doses of oxycodone HCl controlled-release tablets22 
for more than 2 years from previous treating physicians, and 
at the time of her visit to the pain center had been prescribed 
controlled-release oxycodone 60 mg every 8 hours and 
immediate-release oxycodone 5 mg on an as-needed basis 
as rescue medication for breakthrough pain. The patient had 
been using 15 tablets of rescue medication per day, exceeding 
the usual adult dosage of 5 mg every 6 hours.23 There had 
been no subjective evidence of improvement in pain scores 
or increases in functional mobility or quality of life. Review 
of medical records indicated that her pain scores, evalu-
ated using a visual analog scale (VAS) (0–10; 0 = no pain, 
10 = pain as bad as you can imagine), fluctuated, ranging from 
4/10 to 10/10; the patient occasionally visited the emergency 
department for severe pain. The patient was increasingly 
frustrated and scared, and occasionally confused the dos-
ing schedule by mixing up the terms for immediate-release 
and controlled-release oxycodone and took the wrong one. 
The patient also had been previously prescribed citalopram 
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10 mg qd for depression and remained on this medication. 
She had not had any other treatments or modalities before 
coming to the pain center. There was no reported history of 
opioid misuse or abuse.
On her first visit to the pain center, the patient was 
accompanied by her daughter and a mutual friend. The patient 
indicated that her goals were to enhance her quality of life, 
be more active with her children, and improve her overall 
functional mobility. At this visit, a significant amount of time 
was spent educating the patient on opioids in general and 
specifically on the proposed new therapy with MS-sNT, as to 
the rationale of the formulation, proper use, and compliance. 
This counseling and education about her medications helped 
alleviate the patient’s considerable apprehension and anxiety 
over fear of more pain related to the proposed opioid rotation. 
A point-of-service, qualitative drug screen was performed, 
which was positive for prescribed opioids and negative for 
other substances. A written treatment agreement outlining 
expectations, responsibilities, and boundaries (discussed 
below) was signed. Oxycodone extended-release therapy was 
discontinued that day. The patient was instructed to begin 
taking MS-sNT 100 mg every 12 hours beginning the next 
morning. She also was instructed to immediately begin tak-
ing newly prescribed immediate-release oxycodone 15 mg 
as rescue medication for breakthrough pain when needed. 
She was asked to try to limit rescue medication dosing to a 
maximum of three tablets per day.
At her return visit 6 days later, the woman reported 
less pain and a VAS score of 2/10, with occasional break-
through episodes with a VAS score approaching 8/10. The 
patient reported improved ambulation with less limp and 
no significant side effects. Her energy level had improved, 
and she was more active at home. Her daughter was pres-
ent at this visit and concurred. Planned follow-up included 
recording of pain assessments using the Pain Assessment 
and   Documentation Tool (PADT),24 monthly evaluations 
for possible side effects, improvements in activities of daily 
living and functional mobility, referrals to other specialty 
physicians, if applicable, and adjustment of MS-sNT dose 
or adjunct medication.
Case 2
A 50-year-old woman with severe lumbar degenerative disc 
disease and degenerative joint disease, postlaminectomy 
syndrome and bipolar disorder had been treated previously 
with fentanyl transdermal patch 150 µg every 48 hours and 
acetaminophen-hydrocodone 6–8 times per day as rescue 
medication. VAS pain scores were from 7/10 to 8/10.   Medical 
records were negative for indications of opioid misuse or 
abuse. During her interview, the patient expressed that her 
goal was to be more functional in society, be able to go food 
shopping without being in agony, and be more active with 
her family. She was provided with information about opioids 
in general and specifically on the purpose and proper use of 
  MS-sNT. Point-of-service qualitative UDS was performed, 
with results consistent with treatment history, and the written 
treatment agreement was signed. Acetaminophen-hydro-
codone was discontinued that day; MS-sNT was started the 
next morning at 80 mg every 12 hours. Also, morphine sulfate 
immediate release 15 mg, up to a maximum of four tablets 
per day, was to be taken as needed for breakthrough pain.
The patient returned 5 days later accompanied by her 
sister. She reported no side effects but thought that her pain 
relief was inadequate. Her dosage of MS-sNT was increased 
to 100 mg every 12 hours. At a follow-up visit 10 days later, 
the woman reported good pain control, a VAS score of 4/10, 
and no side effects. She said that she only had to use two or 
three doses daily of the rescue medication. She had resumed 
aquatic therapy, had begun being more active, and indicated 
that her quality of life had improved significantly. At this 
follow-up visit, she was accompanied by a family member 
who agreed and was very pleased with her improvement. 
The follow-up plan, as in the preceding case, included 
monthly evaluations and modifications to the treatment plan 
as warranted.
Case 3
A 44-year-old man who is a restaurant chef with progressing 
renal cancer in chemotherapy, complicated by degenerative 
joint disease of the lumbar spine, was referred to the clinic 
for pain management. The patient complained of chronic 
pain in all joints, sternum, burning about the skull, and 
occasional nausea and fatigue from the chemotherapy. At 
the time of his referral, his medications included controlled-
release oxycodone 40 mg bid, oxycodone/acetaminophen25 
325 mg/10 mg 6–8 times daily, and carisoprodol 250 mg 
bid.26 The patient’s VAS pain score was still 7/10, confirming 
that his pain was not relieved. The patient’s treatment goal 
was to be more productive and have better concentration at 
work, as well as to improve his quality of life.
The patient was rotated to MS-sNT 20 mg bid, oxy-
codone/acetaminophen was discontinued, and oxycodone 
15 mg was prescribed for breakthrough pain. After 1 week, 
the patient reported no ill effects or adverse events (AEs), but 
still complained of pain at a VAS score of 7/10. The dose of 
MS-sNT was increased to 30 mg. One week later the patient 
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returned to the clinic stating that he was taking 6–8 doses of 
oxycodone for breakthrough pain and had cut back on his 
work hours due to pain. The patient was counseled to try to 
keep the dosing of breakthrough medications to a minimum 
and the MS-sNT dose was increased to 50 mg bid.
One month later, significant improvement was noted; the 
patient had reduced his breakthrough medication to three 
per day, he was again working full time, his VAS score had 
decreased to 5/10, and there was notable improvement in 
his affect and mood. No AEs were reported. In subsequent 
visits, the patient complained of difficulty swallowing, which 
he attributed to his chemotherapy and disease state. He was 
shown how to break open a capsule of MS-sNT, and sprinkle 
the contents over applesauce. After being reminded of the 
consequences of chewing MS-sNT, the patient was instructed 
to swallow the applesauce and sprinkles without chewing. 
After a few days of following this ritual, the patient resumed 
swallowing the intact MS-sNT in the usual manner. The 
patient has remained on this therapy with acceptable results 
while continuing to receive chemotherapy and engage in 
full-time work.
Discussion
In the three cases presented, patients had chronic pain that 
had been difficult to manage prior to referral. The patients 
presented with pain scores ranging from 4 to 10, despite 
opioid therapy and use of rescue medications as many as 6–8 
or 15 times per day. Pain was interfering with their activities 
of daily living and negatively affecting their quality of life. 
A key component to management of chronic pain is com-
munication, beginning with the history and first consultation 
visit, to ensure that both patient and provider are comfortable 
with the treatment plan and approach.12 At the Pain Center 
of Devon, treatment entails a restructuring of the treatment 
regimen, identification of and agreement on treatment goals, 
monitoring for aberrant drug-related behaviors, and education 
about the properties of MS-sNT. The following are typical 
steps for the management of chronic, moderate-to-severe 
pain in patients who come to the clinic (Table 1).
Prior to the initial visit
Management begins prior to the patient visit, when records 
from the referring and other health care providers are 
reviewed. These records include progress notes, diagnostic 
workup, compliance history, illicit drug use, and the clinically 
judged necessity for opioid analgesics, which are vital to set-
ting a patient’s treatment baseline, documenting the rationale 
for using an opioid, and formulating the treatment plan.10
Initial visit
Review records
When the patient comes for the initial visit, records are 
reviewed again, face-to-face, between the physician and 
patient.1,10,11 Many of these patients have been on high 
doses of medications (most commonly controlled-release 
oxycodone) for years, but they still have a high degree of 
pain and other complaints. In some cases, they may need 
adjunctive therapy, as in the case of neuropathies.
Set baseline and formulate treatment plan,  
establish treatment goals
At this initial visit, the patient is given a physical examination 
and patient-appropriate workup to determine concurrence 
with the diagnostic reports, set patient baseline, and formulate 
a treatment plan. In patients who have previously received 
opioid therapy, this information is useful for ascertaining risk 
for aberrant, opioid-related behaviors. If a patient is opioid 
naïve, screening tools can be used to assist in identifying the 
existence of or risks for opioid misuse, abuse, and addiction, 
as well as the appropriateness of opioid therapy initiation.13
The workup also includes the assessment and man-
agement of opioid-associated complications, such as the 
measurement of hormonal levels.27,28 For example, at the 
Pain Center of Devon, testosterone levels (free, total, and 
dihydroepianderosterone), which are measured in all male 
patients who have been on long-term opioid therapy, are usu-
ally low. Hormone replacement therapy can be considered 
and initiated for these patients.
The physician’s discussion with the patient includes treat-
ment goals to determine what is most important to the patient, 
what is most attainable, what physical level the patient hopes 
to attain within the next year, and what issues the patient is 
having with pain. The overall goal is to regain function at an 
opioid dose that is without intolerable side effects.1,10 Woven 
into the discussion is the universal precautions approach to 
pain management, with the understanding that it is not always 
possible to predict which patients may develop problematic 
opioid use. The possibility of diversion by others is also 
discussed, and patients are encouraged to keep medications 
in a locked cabinet or safe. Such an approach is intended to 
maximize patient care and minimize risk of misuse, abuse, 
and diversion of opioids.11
Patients are requested to undergo urine drug screening. A 
point-of-service qualitative UDS is performed for all patients, 
and samples are sent out for quantitative analysis for metabo-
lite confirmation. Urine drug screening can aid in   determining 
patient compliance with prescribed opioid therapy and 
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detecting use of illicit substances and the presence of opioid 
before opioid therapy is initiated.1,11,12
To allay any fear of potential addiction, it is important 
for patients receiving opioid therapy for the management of 
chronic pain to understand the differences between opioid 
addiction and tolerance, and what potential effects they might 
experience during opioid treatment. Tolerance is a normal 
physiological state of adaptation in which exposure to a given 
dose of drug induces reduced effects over time.29,30 This may 
necessitate dose increases to maintain effectiveness,15 while 
addiction is characterized by behaviors including compulsive 
use, impaired control over drug use, continued use despite 
harm, and craving.29,30
The patient is then made aware of possible risks (such as 
opioid-associated AEs, hyperalgesia, and hormonal changes) 
and benefits associated with opioid therapy.1,11,12 The patient is 
educated on the general management of pain using extended-
release opioids, with an emphasis on the need to strictly adhere 
to the dosing schedule so that potentially serious consequences 
associated with overdosage can be avoided.15
Educate patient about proposed therapy
The features of the MS-sNT formulation, and risks and 
benefits associated with its use are reviewed. The purpose 
of the sequestered naltrexone within the MS-sNT formula-
tion is explained to the patient. If the product is tampered 
with (crushed, chewed, or dissolved), both the morphine and 
naltrexone are rapidly available.15 The dangers of consuming 
tampered MS-sNT, which may precipitate opioid withdrawal 
of extremely variable nature and severity in opioid-tolerant 
Table 1 Summary of steps used at the Pain Center of Devon for management of chronic moderate-to-severe pain and documentation 
of clinical decisions
Visit Steps Purpose
Prior to initial 
visit
Review past medical records. Set baseline; determine total current daily opioid and rescue medication  
use; document rationale for opioid use; formulate treatment plan.
Initial visit Review records again with patient. Establish physician–patient relationship/partnership in pain management.
Conduct thorough patient assessment,  
including physical examination.
Document/verify medical history; determine current pain intensity  
and locations; assess and manage opioid-associated complications.
Determine patient’s treatment goals. Provide opportunity to work with patient to develop  
reasonable, achievable goals.
Administer UDS with confirmatory test. Identify aberrant drug-related behaviors; appropriateness  
of initiating opioid therapy.
Discuss risks/benefits of opioid therapy. Provides patient education and awareness.
Describe proposed new medication and  
provide specific instructions for use, purchase  
from single physician/pharmacist, and storage.
Provide patient education and awareness of expectations for opioid  
use in general and specific features of proposed new medication,  
including potential effects of ingesting tampered product.
Have patient sign a treatment agreement. Establish expectations, responsibilities, boundaries; reinforce physician 
directives for opioid use; may help increase patient compliance.
Encourage inclusion of friend/family member  
in discussions.
Provides confirmation and elaboration of patient report;  
support for patient.
Conversion Switch overnight to half of equianalgesic dose  
of MS-sNT; immediately provide newly prescribed  
immediate-release opioid for breakthrough pain.
Immediately addresses patient’s need for management  
of inadequate pain.
Reevaluate and adjust dose  
every 5–7 days, if needed.
Adjust dose for inadequate pain; address occurrence  
of side effects.
Assesses efficacy and AEs.
Follow-up Monthly longitudinal monitoring  
for compliance.
Documents compliance, effectiveness, side effects, functional  
improvements, progress toward goals, and success of treatment.
Have patient fill out PADT form.
Physician completes section on potential  
aberrant drug-related behavior.
Provides convenient ongoing assessment and quick review of pain  
management over time, including, pain relief, functional changes, mood, sleep,   
AEs, progress towards goals, and documentation of drug-related behaviors.
Examine confirmatory results from UDS;  
counsel if results are unexpected.
Reevaluate and consider nonopioid  
therapies when appropriate.
Determines whether to continue treatment or  
whether discontinuation/referral is needed.
Abbreviations: AE, adverse event; MS-sNT, morphine sulfate and naltrexone hydrochloride extended release capsule; PADT, Pain Assessment and Documentation Tool; 
UDS, urine drug screen.
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patients, are emphasized.20,21 Patient education is most 
important to assure patient awareness of potential effects of 
ingestion of tampered product.
Encourage patient to bring a companion
Patients are encouraged to bring a friend or family member 
to all clinic visits to serve as support for the patient and 
an observer for any concerns. Since patient self-reports 
can be unreliable, involvement of a family member and/
or caregiver as a reliable observer in assessment of the 
patient’s progress during opioid therapy may help verify and 
document assessments of functionality, treatment outcomes, 
and illicit drug use, and may help monitor and respond to 
the occurrence of AEs.1,11 The dialogue that usually ensues 
with a patient’s friends or family members on a follow-up 
visit includes what the observer witnesses in their interac-
tions with the patient. Such observations might include any 
observable changes in mentation, behavior, drowsiness, 
instability, or in the case of conversion to another opioid, 
any improvements in these side effects that may have 
been present with the previous medication. Observations 
from a patient’s friend or family member may include any 
improvements noticed in daily functioning, and quality 
of life in general. A mate can report any improvements in 
sleep patterns, frequency of getting out of the house, or 
complaints about pain.
Treatment agreement
After receiving instructions and discussing the treatment plan 
and goals, the patient is asked to sign a treatment agreement 
(Appendix Figure 1) that documents expectations, respon-
sibilities, and boundaries that patient and physician have 
agreed upon, including the use of one physician and one 
pharmacy for medication, and the possibility of discharge 
from the practice due to certain infractions in the agreement.10 
The written treatment agreement used in this practice is that 
from a consensus of several medical organizations dedicated 
to pain management.31 Patients who do not comply with the 
universal precautions approach and signed treatment agree-
ment are not accepted or treated at the clinic.
Protection of the community is the rationale for using 
a treatment agreement in patients considered for opioid 
therapy. The Federation of State Medical Boards of the 
United States expects physicians to incorporate safeguards 
into their practices to minimize the potential for abuse and 
diversion of opioids.10 Among the consequences of prescrip-
tion opioid abuse are increased cost to patients and health 
care organizations and increased use of health care and 
criminal justice resources.32,33 When offered the explanation 
that such safeguards may keep prescriptions out of the hands 
of   abusers, the author’s experience has been that patients 
have been supportive of this goal and understanding of the 
process. The clinic has not experienced difficulty with getting 
MS-sNT approved with managed care providers.
Conversion
The patients described in the case reports presented here 
were converted to MS-sNT because they had inadequate 
pain control with their previous opioid therapy. The strategy 
of opioid conversion is intended to achieve a better bal-
ance of benefits to harms by switching from one opioid to 
another.1,34,35 The rationale and plan to switch opioids as well 
as what might be expected during this process is explained to 
the patients, who often express concern about the occurrence 
of withdrawal upon discontinuing their medication. Ideally, 
the starting dose of the new opioid should be sufficient to 
prevent withdrawal and produce no worsening of pain, but 
low enough to avoid side effects.34
At the Pain Center of Devon, patients are switched 
overnight to half of an equianalgesic dose of MS-sNT and 
immediately begin taking newly prescribed, immediate-
release opioid for breakthrough pain. Doses of MS-sNT are 
started low because, based on experience, it is preferable 
to make adjustments due to inadequate pain relief than be 
required to titrate downward. The occurrence of disturbing 
side effects can increase patient anxiety and cause the patient 
to be reluctant to use the new medication.
During titration to an effective dose, patients should 
expect to use about 3 doses of breakthrough medication per 
day, although more may be needed occasionally. The clinic 
prefers a titration frequency of every 5–7 days; the patient 
is provided with an MS-sNT prescription for 5–6 days of 
medication only and is scheduled for reevaluation in 5–6 days 
(with early phone-in reports of efficacy, adverse effects, 
and progress). For safety, a patient starting a new opioid 
medication or an increasing dose is warned about potential 
cognitive impairment that may affect driving or work, and 
the patient is reminded that MS-sNT or any opioid should 
not be consumed with alcohol.1,15
Follow-up visits
Management procedures for patients with chronic pain who 
are converted to MS-sNT are the same as with any opioid. 
Subsequent monthly longitudinal monitoring for compliance, 
functional mobility improvements, and side effects, among 
other parameters, is essential for proper management.1 Pain 
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relief and patient goals (improvements in activities of daily 
living and functional mobility) are reviewed to determine 
what progress has been made and whether the treatment 
plan is still appropriate or needs adjustment. During some 
visits, the PADT questionnaire, a clinician-directed interview, 
is administered to the patient. The PADT encompasses 
assessments of analgesia, activities of daily living, AEs, and 
potential aberrant drug-related behavior. The section of the 
PADT concerning potential aberrant drug-related behavior 
is completed by the physician.24 In the clinic, the PADT is 
administered every 6–12 months. At other visits, the patient is 
asked about improvements and changes in functional capac-
ity, sleep, mood, and constipation since the previous visit. 
Patients are again encouraged to include family and/or friends 
to confirm the current situation and offer input.10
If pain relief is inadequate, appropriate adjustments of 
medications including adjunct medications are made. If pain 
fails to respond to opioid therapy, therapy should be discon-
tinued with a gradual tapering off the opioid medication.1 
Referral can be made to other specialists (eg, in the fields of 
psychiatry, orthopedics, and neurology) or to a drug abuse 
specialist/addictionologist, if needed.10
At the follow-up visit, the confirmatory results from the 
UDS are also examined to determine whether the patient 
has been compliant with the signed treatment agreement 
(presence of prescribed medication, absence of prohibited 
illicit substances). If UDS reports are positive for opioids 
other than those prescribed by the clinic, the source of the 
opioid is investigated with the patient. If the opioid was 
leftover from the previous physician, the patient is counseled 
and reminded not to repeat this infraction. If the opioid was 
prescribed by another physician, or if illegal substances are 
detected, the patient is terminated from treatment at the clinic 
and is mailed a letter stating the reasons for termination. 
Patients who are discharged are also offered names of other 
pain physicians who would consider taking them, as well as 
names of treatment facilities for abuse. In some instances, 
the clinic has continued to treat the patient’s pain condition 
with nonscheduled medications or, on occasion, has enrolled 
a patient into the clinic’s buprenorphine/naltrexone treatment 
program.
The clinic has a policy of not allowing early refills more 
than 5 days before schedule, or refills for lost or stolen 
medications. As a result, the clinic has not had any reported 
cases of lost or stolen medication or requests for early refills. 
The clinic has had similar success using this approach with 
patients taking morphine sulfate extended-release36 prior to 
the availability of MS-sNT.
Costs and benefits of responsible monitoring  
for opioid-related aberrant behavior
At the Pain Center of Devon, patients have not encountered 
difficulty with their health care plans and reimbursement for 
MS-sNT prescriptions. While the time required to manage 
any patient with chronic pain is substantial, perhaps the 
greatest material costs may be associated with the urine drug 
screening. As we believe that the qualitative on-the-spot UDS 
is indispensible in providing a snapshot of what to expect 
from each patient, the clinic pays for the point-of-service 
specimen cups, and the testing is typically reimbursed by 
Medicare and some private payers. In addition, the toxicol-
ogy laboratory provides a person to perform collections at 
the center’s office for quantitative analysis. This individual is 
responsible for collection and handling of the urine specimen, 
filling out associated forms, having the patient sign the speci-
men cup and form, and packing the specimens for shipment 
for quantitative analysis. The toxicology laboratory bills the 
insurance company directly. Additional time on the part of 
clinic personnel is required for receipt, interpretation and 
follow-up of results, and chart filing and handling; however, 
this time is well spent, as it enables us to provide responsible 
monitoring of patients so that problematic behaviors can be 
addressed immediately.
Outside of the clinic and community setting, misuse and 
abuse of opioids lead to substantial direct and indirect costs. 
Based on analysis of a claims database covering 2 million 
members from 16 large employers, between 1998 and 2002, 
opioid abusers aged between 12 and 64 years had higher 
usage rates of medical services, with total average per patient 
direct health payer costs estimated at US$15,884, more than 
eightfold higher than that of nonopioid abusers at US$1830 
(P , 0.01).37 Additional costs result from consequent reduced 
productivity, prescription opioid theft, criminal activity, and 
strategies required to monitor, prevent, and deter misuse and 
abuse; however, there is limited information published about 
the costs of initiatives designed to reduce misuse, abuse, 
and diversion. A budget-impact model was used to estimate 
substantial savings to US third-party payers ranging from 
US$0.6 billion to US$1.6 billion per year resulting from 
introduction of a theoretical opioid formulation designed to 
resist or deter common methods of abuse. In addition, the 
public health consequences of opioid misuse and abuse would 
potentially be avoided.38
Conclusion and future perspective
Tailoring chronic pain management to individual patients, as 
is necessary with opioid therapy,1 may be best accomplished 
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by combining evidenced-based medicine from clinical guide-
lines and practitioner experience. These cases demonstrate 
that several measures can enable the practitioner to both 
optimize pain-related outcomes and gain patient acceptance 
of formulations that incorporate a unique technology; these 
include the communication between physician and patient 
that accompanies complete pretreatment assessment, set-
ting of treatment goals and expectations, proper instruction 
regarding the purpose and use of medications, and attention 
to individual patient issues.11 It is likely that in the future, 
most long-acting opioid preparations will include features 
designed to resist tampering, misuse, and abuse. Presumably, 
reduced likeability and tamper-resistance will decrease the 
desire and/or ability to abuse those opioid formulations by 
chewing, injecting, or snorting to obtain an instant high. 
Epidemiological studies will be needed to determine the 
impact of such formulations on misuse, abuse, and diversion 
of opioids in the community. In the meantime, communica-
tion and patient education are important to maximize the 
attainment of pain management goals while minimizing the 
risk of unintended consequences.
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The purpose of this Agreement is to prevent misunderstandings about certain medicines
you will be taking for pain mangement. This is to help both you and your doctor to
comply with the law regarding controlled pharmaceuticals.
SAMPLE MODEL PAIN MANAGEMENT AGREEMENT
I understand that this Agreement is essential to the trust and confidence necessary in a
doctor/patient relationship and that my doctor undertakes to treat me based on this
Agreement.
I understand that if I break this Agreement, my doctor will stop prescribing these pain-
control medicines.
In this case, my doctor will taper off the medicine over a period of several days, as
necessary, to avoid withdrawal symptoms. Also, a drug-dependence treatment program
may be recommended.
I will communicate fully with my doctor about the character and intensity of my pain, the
effect of the pain on my daily life, and how well the medicine is helping to relieve the
pain.
I will not use any illegal controlled substances, including marijuana, cocaine, etc.
I will not share, sell or trade my medication with anyone.
I will not attempt to obtain any controlled medicines, including opioid pain medicines,
controlled stimulants, or antianxiety medicines from any other doctor.
I will safeguard my pain medicine from loss or theft. Lost or stolen medicines will not be
replaced.
I agree that refills of my prescriptions for pain medicine will be made only at the time of
an office visit or during regular office hours. No refills will be available during evenings
or on weekends.
I agree to use
I agree that I will submit to a blood or urine test if requested by my doctor to determine
my compliance with my program of pain control medicine.
American Academy of Pain Management • 13947 Mono Way #A • Sonora, CA95370 • Phone: 209-533-9744
Fax: 209-533-9750 • e-mail: aapm@aapainmanage.org • www.aapainmanage.org
located at
telephone number
of my pain medicine.
I authorize the doctor and my pharmacy to cooperate fully with any city, state or federal
law enforcement agency, including this state’s Board of Pharmacy, in the investigation
of any possible misuse, sale, or other diversion of my pain medicine. I authorize my
doctor to provide a copy of this Agreement to my pharmacy. I agree to waive any
applicable privilege or right of privacy or confidentiality with respect to these
authorizations.
Pharmacy,
,
, for filling prescriptions for all
Appendix Figure 1 Sample model pain management agreement.3
Note: Reproduced with permission of the American Academy of Pain Management.
Appendix
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